Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Updates

-- Clinical trials of core drug candidates are progressing steadily with the debut of the company's FIH asset -- Toripalimab's sales performance is consistently improving; the US BLA is under review SHANGHAI

Related Keywords

Jilin ,China ,Wujiang ,Jiangsu ,Shanghai ,United States ,Suzhou ,Lingang ,Jiangxi ,Canada ,Chinese ,American ,Junshi Bioscience ,Junshi Biosciences ,Zhi Li ,Acta Pharmacologica Sinica ,American Society Of Clinical Oncology ,Coherus Biosciences Inc ,Wigen Biomedicine Technology Shanghai Co Ltd ,China Securities Regulatory Commission ,European Union ,National Medical Products Administration Of China ,Pr Team ,Risen Suzhou Biosciences Co Ltd ,Ir Team ,Drug Administration ,European Commission ,Shanghai Stock Exchange ,Sun Yat Sen University Cancer Center ,Shanghai Lingang Production ,European Medicines Agency ,National Drug List For Basic Medical Insurance ,Shanghai Junshi Biosciences Co Ltd ,Shanghai City ,Investigational New Drug ,National Medical Products Administration ,United States Food ,Signal Transduction ,Targeted Therapy ,American Society ,Clinical Oncology ,Biologics License Application ,Prescription Drug User Fee Act ,National Drug List ,Basic Medical Insurance ,Work Related Injury Insurance ,Maternity Insurance ,Coherus Biosciences ,Wigen Biomedicine Technology ,Immune Checkpoint ,Shanghai Lingang Production Base ,China Securities Regulatory ,Chinese Academy ,Emergency Use Authorizations ,Junshi ,Iosciences ,Nnounces ,022 ,Interim ,Financial ,Results ,Rovides ,Corporate ,Updates ,